Generalitat de Catalunya

TECHNOLOGY CENTERS IN CATALONIA

TECNIO certification and main R&D players in Catalonia


Header Tecnio
Anti-cancer & metastasis antibody
International patent granted(National phases).

Anti-metastasin is a therapeutic monoclonal antibody that inhibits the alarmin S100A4, and blocks cancer progression and metastasis dissemination. The antibody has also diagnostic and prognostic uses as an ELISA test and immunohistochemistry. Humanized therapeutic antibody with preclinical proof of concept
Absolutely safe since target is not experssed in healthy tissues (no side effects in experimental models)
Universal mechanism of action: useful to treat many cancer indications

TECHNOLOGY DESCRIPTION

Anti-metastasin is a humanized monoclonal antibody that inhibits S100A4 alarmin. Alarmins are soluble factors that are absent in normal tissues, but which are over-expressed in many aggressive cancers. Its over-expression in biofluids is clinically associated with a poor prognosis in many cancers and represents a universal mechanism of malignancy in almost all aggressive cancers, becoming a good therapeutic target, diagnosis and prognosis.
The antibody blocks the progression of the tumor and the metastatic dissemination in several indications of cancer in animal models.
In addition, S100A4 can also be used as a stratification biomarker of the patient, such as a serological marker with prognostic value, and to control the response to treatment and resistance to anti-cancer treatments.
We have an ELISA test for diagnosis / prognosis and antibodies for immunohistochemistry in cryopreserved and parafinined samples.

The target mechanism of action as well as the in vivo proof of principle of the antibody as therapeutic agent have been demonstrated. Moreover, the target itself has also been validated as prognostic biomarker in clinical samples from cancer patients in several oncologic indications. Additionally, mAb humanization process is already performed and a master cell bank is being established. In addition to the functional and pharmaceutical activity a cross-species specific analysis (IHC) has been performed in order to determine the candidate species for the toxicological studies (rodent and non-rodent).

BUSINESS OPPORTUNITY

Triple mechanism of action and total safety:
> Control of tumor growth & metastatic spread
> Control of tumor angiogenesis
> Blocking of the resistance to chemotherapeutic agents
IPR protection:
> Patent (therapy, diagnosis, oncology & inflammation)
> Antibody is "first-in-class”
> Proprietary associated ELISA & IHC tests (companion diagnostics/prognostics)

Co-development. A pahrmaceutical / biotech / diagnostic partner is sought for either licensing or co-development. Other strategies are also possible.

APPLICATION

The therapeutic antibody can be used to treat many cancer indications and is of special relevance to the more agressive and metastatic cancers.
The diagnosis and prognosis tests can be used for both diagnosis of suspect cancers, for prognosis of cancer patient evolution, for patient stratification before treatment, and for treatment monitoring,

Pharmaceutical companies
Biotech companies
Diagnostic companies
Medical device companies
Venture Capital and investors

Biotechnology

Some sub-sectors in the field of "Health Industries".

STATE OF MATURITY
Research
Development
Exploitation

We reached in vivo proof of concept of the antibody as a therapeutic agent, diagnosis and prognosis

STATE OF INTELLECTUAL AND INDUSTRIAL PROPERTY

International patent granted(National phases). LYKERA BIOMED (100%).

ADDITIONAL MATERIAL
LEITAT Tecnological Center
FRANCESC MITJANS
934020417
Health & Biomedicine
Anti-cancer & metastasis antibody
International patent granted(National phases).

Anti-metastasin is a therapeutic monoclonal antibody that inhibits the alarmin S100A4, and blocks cancer progression and metastasis dissemination. The antibody has also diagnostic and prognostic uses as an ELISA test and immunohistochemistry. Humanized therapeutic antibody with preclinical proof of concept
Absolutely safe since target is not experssed in healthy tissues (no side effects in experimental models)
Universal mechanism of action: useful to treat many cancer indications

TECHNOLOGY DESCRIPTION

Anti-metastasin is a humanized monoclonal antibody that inhibits S100A4 alarmin. Alarmins are soluble factors that are absent in normal tissues, but which are over-expressed in many aggressive cancers. Its over-expression in biofluids is clinically associated with a poor prognosis in many cancers and represents a universal mechanism of malignancy in almost all aggressive cancers, becoming a good therapeutic target, diagnosis and prognosis.
The antibody blocks the progression of the tumor and the metastatic dissemination in several indications of cancer in animal models.
In addition, S100A4 can also be used as a stratification biomarker of the patient, such as a serological marker with prognostic value, and to control the response to treatment and resistance to anti-cancer treatments.
We have an ELISA test for diagnosis / prognosis and antibodies for immunohistochemistry in cryopreserved and parafinined samples.

The target mechanism of action as well as the in vivo proof of principle of the antibody as therapeutic agent have been demonstrated. Moreover, the target itself has also been validated as prognostic biomarker in clinical samples from cancer patients in several oncologic indications. Additionally, mAb humanization process is already performed and a master cell bank is being established. In addition to the functional and pharmaceutical activity a cross-species specific analysis (IHC) has been performed in order to determine the candidate species for the toxicological studies (rodent and non-rodent).

BUSINESS OPPORTUNITY

Triple mechanism of action and total safety:
> Control of tumor growth & metastatic spread
> Control of tumor angiogenesis
> Blocking of the resistance to chemotherapeutic agents
IPR protection:
> Patent (therapy, diagnosis, oncology & inflammation)
> Antibody is "first-in-class”
> Proprietary associated ELISA & IHC tests (companion diagnostics/prognostics)

Co-development. A pahrmaceutical / biotech / diagnostic partner is sought for either licensing or co-development. Other strategies are also possible.

APPLICATION

The therapeutic antibody can be used to treat many cancer indications and is of special relevance to the more agressive and metastatic cancers.
The diagnosis and prognosis tests can be used for both diagnosis of suspect cancers, for prognosis of cancer patient evolution, for patient stratification before treatment, and for treatment monitoring,

Pharmaceutical companies
Biotech companies
Diagnostic companies
Medical device companies
Venture Capital and investors

Biotechnology

Some sub-sectors in the field of "Health Industries".

STATE OF MATURITY
Research
Development
Exploitation

We reached in vivo proof of concept of the antibody as a therapeutic agent, diagnosis and prognosis

STATE OF INTELLECTUAL AND INDUSTRIAL PROPERTY

International patent granted(National phases). LYKERA BIOMED (100%).

ADDITIONAL MATERIAL
LEITAT Tecnological Center
FRANCESC MITJANS
934020417
Health & Biomedicine